Sign In
Buy GMAB
$23.88
+0.0300 (+0.126%)
At Close: Jun 03, 2026
Passing of Genmab A/S' Annual General Meeting
10:23am, Wednesday, 12'th Mar 2025
Company Announcement At Genmab A/S' Annual General Meeting held today March 12, 2025, the Annual Report for 2024 was approved Discharge was given to the Board of Directors and the Executive Manage
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
10:21am, Monday, 10'th Mar 2025
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop,
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
10:13am, Monday, 10'th Mar 2025
Company Announcement Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue fu
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
11:58am, Tuesday, 04'th Mar 2025
Company Announcement COPENHAGEN, Denmark; March 4, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, t
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
04:04pm, Friday, 28'th Feb 2025
Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/52
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
04:00pm, Friday, 28'th Feb 2025
Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 614,676 restricted stock units to members of management and em
Capital Increase in Genmab as a Result of Employee Warrant Exercise
02:30pm, Tuesday, 25'th Feb 2025
Company Announcement COPENHAGEN, Denmark; February 25, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,058 shares as a consequence of the exercise of employee warrants. The in
Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference
09:14am, Wednesday, 19'th Feb 2025
Media Release COPENHAGEN, Denmark; February 19, 2025 Genmab A/S (Nasdaq: GMAB ) announced today that its C hief F inancial O fficer Anthony Pagano and C hief D evelopment O fficer Judith Klimovsky wil
Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon
02:25am, Tuesday, 18'th Feb 2025
Genmab reported strong Q4 2024 results, with $897.4 million in revenue, beating expectations and showing 29% Y/Y growth, driven by Darzalex royalties. 2025 revenue guidance was slightly ahead of conse
Genmab A/S (GMAB) Q4 2024 Earnings Conference Call Transcript
09:32am, Friday, 14'th Feb 2025
Genmab A/S (GMAB) Q4 2024 Earnings Conference Call February 12, 2025 12:00 PM ET Company Participants Jan van de Winkel - CEO Brad Bailey - EVP and Chief Commercial Officer Anthony Pagano - CFO Tahamt
Notice to Convene the Annual General Meeting of Genmab A/S
06:00am, Thursday, 13'th Feb 2025
Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 12, 2025 COPENHAGEN, Denmark; February 13, 2025 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on We
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
01:14pm, Wednesday, 12'th Feb 2025
Media Release COPENHAGEN, Denmark; February 12, 2025 Genmab filed Form 20-F for the financial year 2024 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report
Genmab Publishes 2024 Annual Report
11:01am, Wednesday, 12'th Feb 2025
Company Announcement COPENHAGEN, Denmark; February 12, 2025 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024
Grant of Restricted Stock Units and Warrants to Employees in Genmab
03:08pm, Thursday, 23'rd Jan 2025
Company Announcement COPENHAGEN, Denmark; January 23, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 4,903 restricted stock units and 5,289 warrants to employees of
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
06:23am, Wednesday, 22'nd Jan 2025
Company Announcement Net sales of DARZALEX ® in 2024 totaled USD 11,670 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPEN
